Operated jointly by the Yale University School of Medicine Department of Psychiatry and Connecticut Mental Health Center, the Yale Depression Research Program has, for over 30 years, been committed to advancing the treatment of depression. By engaging in studies that seek to elucidate the underlying neurobiology of depression, we are striving to improve our ability to diagnose and treat mood disorders.
Thank you for your interest in our ketamine study, Examining the Impact of Sirolimus on Ketamine’s Antidepressant Response, advertised on a billboard in New Haven. The aim of the study is to provide insight into the impact of the immunosuppressants drug, sirolimus, on the antidepressant effects of the antidepressant medication, ketamine. This study is enrolling study participants between the ages of 18-65, with a diagnosis of depression or bipolar disorder and a history of trialing one or more antidepressant medications with little to no symptom improvement. Enrolled participants will receive active ketamine. The study requires availability during the week for participating in study visits. Participants are compensated for their time. We do have some flexibility to provide transportation and hotel accommodations for study visits based on need, determined on a case-by-case basis.
For more information about this, and other studies in the Emerge Research Program, please contact us at 203-932-5711, ext. 5044, 203-985-5281, or at email@example.com. You can also find out more information here.